MedTrace Logo

Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders

NCT00897260 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-01-26

No results posted yet for this study

Summary

To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.

Conditions

  • Hematological Malignancy
  • Bone Marrow Failure Syndrome

Interventions

DRUG

Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis. DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x * Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x * Fludarabine dose adjustment: 70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight. UCB Infusion

RADIATION

Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x

PROCEDURE

Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Donna Hogge · University of British Columbia - Vancouver Coastal Health Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-01-09
Completion
2013-01-09

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897260 on ClinicalTrials.gov